Form 4 for PCVX Vaxcyte, Inc.
Accepted 2022-12-28 00:00:00 ET · period of report 2022-12-23 · accession 0001209191-22-062845 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-28 | 2022-12-23 | PCVX | Wassil Jim | COO | M - OptEx | $2.42 | +105.4K | 147.7K | +249% | +$255.0K |
| D | 2022-12-28 | 2022-12-23 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -105.4K | 116.6K | -47% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-23 | M | A | 105,371 | $2.42 | 147,715 | D | — | — | (F1) The shares of Common Stock received upon this option exercise remain subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 24, 2022. |
| 2 | Derivative | Stock Option (right to buy) | 2022-12-23 | M | D | 105,371 | $0.00 | 116,555 | D | $2.42 · — to 2029-12-16 | 105,371 Common Stock | (F2) 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. |